Regenxbio. Every tracked FinTwit mention of $RGNX, newest first. 14 mentions since the first on Oct 8, 2025. See the price chart.
May 2026 · 3 mentions
May 14
Adam Feuerstein ✡️ — @pemulisking Approval standard is the biggest overhang, I think. $RGNX single-arm study using correlative analysis to link microD expression to muscle benefit vs $SLDB going with a…↗
Adam Feuerstein ✡️ — $RGNX Duchenne gene therapy study results are out: microdystrophin expression reached an average of 71% of normal across all 31 boys at 12 wks. Functional improvements in a subset…↗
March 2026 · 1 mention
Mar 19
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter:
Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era
$REPL Pierre Fabre $ATRA $QURE $CAPR $RGNX
https://t.co…↗
February 2026 · 6 mentions
Feb 26
Adam Feuerstein ✡️ — (Hopefully) Final word today on the Makary $QURE (or was it $RGNX) thing:
Bottom line: Makary shouldn't be talking publicly about unresolved drug applications. Uniqure doesn't ev…↗
Feb 26
Adam Feuerstein ✡️ — @BiotechAnalysst $RGNX therapy is delivered intrathecally into the spine, not via a burr hole in the head like $QURE↗
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter: The old Vinay Prasad never left. He just changed jobs
Submissions to the FDA are handled by teams of reviewers, of course. But when I lo…
January 2026 · 3 mentions
Jan 28
Adam Feuerstein ✡️ — $RGNX A question that is likely to come up today -- How different or similar are the MPS gene therapies to RGX-202, its gene therapy for DMD? I asked the company:
"RGX-202 which…↗
Jan 28
Adam Feuerstein ✡️ — BREAKING: FDA halts $RGNX gene therapy trials after brain tumor found in patient.
Tumor found in patient treated with MPS I therapy. FDA placed hold on it and the MPS II therapy.…↗
Jan 12
Adam Feuerstein ✡️ — $SRPT Elevidys Q4 sales $110M vs consensus $120M
At his #JPM26 presentation, CEO Doug Ingram notes 80% of addressable ambulatory DMD patients remain untreated. He sees this a huge…↗
Adam Feuerstein ✡️ — FDA rejects Regenxbio’s $RGNX rare-disease gene therapy
Agency raised questions about the surrogate biomarker used to predict clinical benefit in Hunter syndrome
https://t.co/LZSIH…↗